Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 1497879, 7 pages
https://doi.org/10.1155/2018/1497879
Research Article

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas

1Department of Obstetrics and Gynecology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
2Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland

Correspondence should be addressed to Pawel Sadlecki; lp.pw@ikceldaslewap

Received 18 October 2017; Revised 31 December 2017; Accepted 30 January 2018; Published 25 February 2018

Academic Editor: Dario de Biase

Copyright © 2018 Pawel Sadlecki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Anderson, “Laboratory methods for KRAS mutation analysis,” Expert Review of Molecular Diagnostics, vol. 11, no. 6, pp. 635–642, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Dudley, G. T. Gurda, L. H. Tseng et al., “Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma,” Molecular Diagnosis & Therapy, vol. 18, no. 4, pp. 409–418, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. C. T. Harbison, C. E. Horak, J. M. Ledeine et al., “Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial,” Archives of Pathology & Laboratory Medicine, vol. 137, no. 6, pp. 820–827, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. D. de Biase, C. de Luca, G. Gragnano et al., “Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates,” Journal of Clinical Pathology, vol. 69, no. 11, pp. 986–991, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Sadlecki, P. Walentowicz, M. Bodnar, A. Marszalek, M. Grabiec, and M. Walentowicz-Sadlecka, “Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers,” Tumor Biology, vol. 39, no. 5, article 101042831770623, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Berek, C. Crum, and M. Friedlander, “Cancer of the ovary, fallopian tube, and peritoneum,” International Journal of Gynecology & Obstetrics, vol. 119, pp. S118–S129, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. P. Grabowski, P. Harter, F. Heitz et al., “Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase,” Gynecologic Oncology, vol. 140, no. 3, pp. 457–462, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Gourley, J. Farley, D. M. Provencher et al., “Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas,” International Journal of Gynecological Cancer, vol. 24, Supplement 3, no. 9, pp. S9–S13, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Malpica and M. T. Deavers, “Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary,” International Journal of Gynecological Pathology, vol. 30, no. 6, pp. 613–619, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. D. M. Gershenson, E. G. Silva, G. Tortolero-Luna, C. Levenback, M. Morris, and C. Tornos, “Serous borderline tumors of the ovary with noninvasive peritoneal implants,” Cancer, vol. 83, no. 10, pp. 2157–2163, 1998. View at Publisher · View at Google Scholar
  12. T. May, C. Virtanen, M. Sharma et al., “Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary,” Gynecologic Oncology, vol. 117, no. 1, pp. 9–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. N. Kwong, J. C. Costello, H. Liu et al., “Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma,” Nature Medicine, vol. 18, no. 10, pp. 1503–1510, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. I. A. Prior, P. D. Lewis, and C. Mattos, “A comprehensive survey of Ras mutations in cancer,” Cancer Research, vol. 72, no. 10, pp. 2457–2467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Emmanuel, Y.-E. Chiew, J. George et al., “Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver,” Clinical Cancer Research, vol. 20, no. 24, pp. 6618–6630, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Basta, M. Bidziński, A. Bieńkiewicz et al., “Rekomendacje Polskiego Towarzystwa Ginekologii Onkologicznej dotyczące diagnostyki i leczenia raka jajnika,” 2015, http://ptgo.pl/dla-lekarza/rekomendacje-i-zalecenia/.
  17. J. Prat and FIGO Committee on Gynecologic Oncology, “Staging classification for cancer of the ovary, fallopian tube, and peritoneum,” International Journal of Gynaecology & Obstetrics, vol. 124, no. 1, pp. 1–5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Hauptmann, K. Friedrich, R. Redline, and S. Avril, “Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria,” Virchows Archiv, vol. 470, no. 2, pp. 125–142, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. Technical sheet Idylla™ NRAS Mutation Test.
  20. P. P. Roux and J. Blenis, “ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions,” Microbiology and Molecular Biology Reviews, vol. 68, no. 2, pp. 320–344, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Castellano and J. Downward, “Role of RAS in the regulation of PI 3-kinase,” Current Topics in Microbiology and Immunology, vol. 346, pp. 143–169, 2010. View at Publisher · View at Google Scholar
  22. E. Hodis, I. R. Watson, G. V. Kryukov et al., “A landscape of driver mutations in melanoma,” Cell, vol. 150, no. 2, pp. 251–263, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Malumbres and M. Barbacid, “RAS oncogenes: the first 30 years,” Nature Reviews Cancer, vol. 3, no. 6, pp. 459–465, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Haley, L. H. Tseng, G. Zheng et al., “Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers,” Modern Pathology, vol. 28, no. 10, pp. 1390–1399, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Daud and B. C. Bastian, “Beyond BRAF in melanoma,” Current Topics in Microbiology and Immunology, vol. 355, pp. 99–117, 2012. View at Publisher · View at Google Scholar
  26. I. V. Fedorenko, G. T. Gibney, and K. S. M. Smalley, “NRAS mutant melanoma: biological behavior and future strategies for therapeutic management,” Oncogene, vol. 32, no. 25, pp. 3009–3018, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Van Cutsem, A. Cervantes, B. Nordlinger, and D. Arnold, “Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 25, Supplement 3, pp. iii1–iii9, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. A. B. Benson 3rd, A. P. Venook, L. Cederquist, E. Chan, Y. J. Chen, and H. S. Cooper, “Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network, vol. 15, no. 3, pp. 370–398, 2016. View at Google Scholar
  29. N. N. Vagaja, J. Parry, D. McCallum, M. A. Thomas, and J. M. Bentel, “Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma,” Journal of Clinical Pathology, vol. 68, no. 8, pp. 657–660, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. K. M. Haigis, K. R. Kendall, Y. Wang et al., “Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon,” Nature Genetics, vol. 40, no. 5, pp. 600–608, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Sadlecki, P. Antosik, D. Grzanka, M. Grabiec, and M. Walentowicz-Sadlecka, “KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system,” Tumor Biology, vol. 39, no. 10, article 101042831773398, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Xing, Y. Suryo Rahmanto, F. Zeppernick et al., “Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma,” Human Pathology, vol. 68, pp. 87–91, 2017. View at Publisher · View at Google Scholar · View at Scopus
  33. S. C. Chang, P. C. Lin, J. K. Lin et al., “Mutation spectra of common cancer-associated genes in different phenotypes of colorectal carcinoma without distant metastasis,” Annals of Surgical Oncology, vol. 23, no. 3, pp. 849–855, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Fakhruddin, M. Jabbour, M. Novy et al., “BRAF and NRAS mutations in papillary thyroid carcinoma and concordance in BRAF mutations between primary and corresponding lymph node metastases,” Scientific Reports, vol. 7, no. 1, p. 4666, 2017. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Yang, X. Lyu, X. Zhu et al., “Chromosome t(7;11)(p15;p15) translocation in acute myeloid leukemia coexisting with multilineage dyspoiesis and mutations in NRAS and WT1: a case report and literature review,” Oncology Letters, vol. 13, no. 5, pp. 3066–3070, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. M. V. Heppt, T. Siepmann, J. Engel et al., “Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care,” BMC Cancer, vol. 17, no. 1, p. 536, 2017. View at Publisher · View at Google Scholar
  37. E. Muñoz-Couselo, E. Zamora Adelantado, C. Ortiz Vélez, J. Soberino-García, and J. M. Perez-Garcia, “NRAS-mutant melanoma: current challenges and future prospect,” OncoTargets and Therapy, vol. 10, pp. 3941–3947, 2017. View at Publisher · View at Google Scholar · View at Scopus
  38. J. A. Jakob, R. L. Bassett Jr., C. S. Ng et al., “NRAS mutation status is an independent prognostic factor in metastatic melanoma,” Cancer, vol. 118, no. 16, pp. 4014–4023, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Dummer, D. Schadendorf, P. A. Ascierto et al., “Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial,” The Lancet Oncology, vol. 18, no. 4, pp. 435–445, 2017. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Wang, S. Velho, E. Vakiani et al., “Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression,” Cancer Discovery, vol. 3, no. 3, pp. 294–307, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Lasota, A. Kowalik, A. Felisiak-Golabek et al., “SP174, NRAS Q61R mutant-specific antibody, cross-reacts with KRAS Q61R mutant protein in colorectal carcinoma,” Archives of Pathology & Laboratory Medicine, vol. 141, no. 4, pp. 564–568, 2017. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Therkildsen, T. K. Bergmann, T. Henrichsen-Schnack, S. Ladelund, and M. Nilbert, “The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis,” Acta Oncologica, vol. 53, no. 7, pp. 852–864, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. E. R. Fearon, “Molecular genetics of colorectal cancer,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, no. 1, pp. 479–507, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. P. A. Ascierto, D. Schadendorf, C. Berking et al., “MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study,” The Lancet Oncology, vol. 14, no. 3, pp. 249–256, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. S. S. Sam, K. A. Lebel, C. L. Bissaillon, L. J. Tafe, G. J. Tsongalis, and J. A. Lefferts, “Automation of genomic DNA isolation from formalin-fixed, paraffin-embedded tissues,” Pathology - Research and Practice, vol. 208, no. 12, pp. 705–707, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Janku, B. Claes, H. J. Huang et al., “BRAF mutation testing with a rapid, fully integrated molecular diagnostics system,” Oncotarget, vol. 6, no. 29, pp. 26886–26894, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. J. R. Dijkstra, D. A. M. Heideman, G. A. Meijer et al., “KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance,” Virchows Archiv, vol. 462, no. 1, pp. 39–46, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Weyn, S. Van Raemdonck, R. Dendooven et al., “Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples,” BMC Cancer, vol. 17, no. 1, p. 139, 2017. View at Publisher · View at Google Scholar · View at Scopus